Peripheral neuropathy Board decisions

The Board granted a 100 percent rating for PTSD and depressive disorder with insomnia from December 29, 2020, but denied increased ratings for the veteran's other conditions.

The Board denied higher ratings for the Veteran's left and right lower extremity radiculopathy with diabetic peripheral neuropathy, but granted separate 20 percent ratings from October 28, 2024, for left and right lower extremity radiculopathy affecting the femoral nerve. The Board also denied higher ratings for the Veteran's left and right upper extremity peripheral neuropathy.

The Board remands the claims for an earlier effective date and to obtain medical opinions on whether the Veteran's sleep apnea is secondary to his sarcoidosis, and whether his peripheral neuropathy of the bilateral upper and lower extremities are due to his service-connected sarcoidosis.

The Board remands the claims for further development, including additional examinations to address the impact of medication on the Veteran's neuropathy and to determine the nature and etiology of his GERD.

The Veteran withdrew his appeals for service connection for skeletal arthritis, a bilateral eye disorder, and peripheral neuropathy in both upper extremities.

The Board denied an initial increased rating in excess of 10 percent for both left and right lower extremity diabetic peripheral neuropathy as the evidence did not support moderate incomplete paralysis of the sciatic nerve group.

The Board denied service connection for diabetes mellitus type II and remanded the claim for further development regarding neuropathy of the left lower extremity.

The Board granted an effective date of April 26, 2018, for the award of service connection for multiple sclerosis and associated conditions, chronic migraine headaches, and trigeminal neuralgia.

The Veteran is granted SMC benefits based on the loss of use of both feet and hands, as well as other conditions entitling him to additional SMC.

The Board denied service connection for diabetes mellitus, type II and related conditions due to a lack of evidence linking the Veteran's current disabilities to his active service or toxic exposure at Camp Lejeune.

The Board granted service connection for lumbar disorders (strain and spondylosis) and bilateral lower extremity peripheral neuropathy, finding that the evidence is nearly equal that these conditions are related to the Veteran's active-duty service.

The appeal for service connection and eligibility related to right lower extremity peripheral neuropathy with amputation residuals, specially adapted housing, and special home adaptation grant has been withdrawn by the Veteran's representative.

The Board granted an earlier effective date of August 29, 2024, for the award of a 20 percent rating for service-connected diabetic neuropathy of the left and right lower extremity.

The Board granted service connection for lumbar spine degenerative disc disease and coronary artery disease associated with herbicide agent exposure. Bilateral hearing loss was denied.

The Board granted service connection for ischemic optic neuropathy as secondary to the Veteran's service-connected carcinoma of glottis and laryngeal cancer, but denied service connection for tooth decay.

The Veteran's appeal for increased ratings was denied, except for a grant of TDIU effective May 30, 2023.

The Board denied service connection for hernia, brain tumor, heart, esophagus, kidney, left lower extremity peripheral neuropathy, right lower extremity peripheral neuropathy, and thyroid. The claim for bilateral hearing loss was remanded.

The Board denied an increased rating for lumbosacral strain but granted separate ratings of 10 percent each for right and left lower extremity neuropathy of the anterior tibial nerve.

The Board remands the claim for a right foot disability, to include plantar fasciitis and neuropathy, as there is no adequate VA medical opinion regarding these conditions.

The Board granted service connection for diabetic retinopathy, peripheral neuropathy of the upper extremities, kidney condition, obstructive sleep apnea, asthma, and tinnitus.